Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 29;227(11):1335-1336.
doi: 10.1093/infdis/jiac489.

Response to Fullarton et al

Alexia Kieffer  1 , Matthieu Beuvelet  1 , Aditya Sardesai  2 , Robert Musci  2 , Sandra Milev  2 , Jason K H Lee  3
Affiliations
Editorial

Response to Fullarton et al

Alexia Kieffer et al. J Infect Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. A. K., M. B., and J. K. H. L. are employees of Sanofi and may hold shares and/or stock options in the company. A. S, R. M., and S. M. are salaried employees of Evidera and are not allowed to accept remuneration from any clients for their services. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Comment on

References

    1. Fullarton J, Keary I, Paes B, Tarride JE, Carbonell-Estrany X, Rodgers-Gray B. Accurately assessing the expected impact of universal first respiratory syncytial virus (RSV) season immunization with nirsevimab against RSV-related outcomes and costs among all US infants. J Infect Dis 2023; 227:1333–4. - PubMed
    1. Kieffer A, Beuvelet M, Sardesai A, et al. . Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model. J Infect Dis 2022; 226(suppl 2):S282–92. - PMC - PubMed
    1. Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine 2020; 38:251–7. - PMC - PubMed
    1. Pavilack M, Clifford RA, Gonzales T, Kong AM, Wade S, McLaurin KK. Trends in utilization of outpatient respiratory syncytial virus prophylaxis with palivizumab among Medicaid-and commercially insured infants. Infect Dis Ther 2018; 7:121–34. - PMC - PubMed
    1. Swedish Orphan Biovitrum (Sobi) . Annual and sustainability report 2021. https://www.sobi.com/sites/default/files/pr/202204055842-1.pdf. Accessed December 1, 2022.